OmniAb (OABI) Net Cash Flow (2021 - 2026)
OmniAb (OABI) posted quarterly Net Cash Flow of $3.5 million for Q1 2026, up 121.08% year-over-year from $1.6 million in Q1 2025, and up 216.89% quarter-over-quarter from -$3.0 million in Q4 2025.
OmniAb (OABI) Net Cash Flow (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Net Cash Flow for 6 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 121.08% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $18.2 million (up 322.26% YoY), while the FY2025 annual figure was -$2.1 million, down 118.45% from the prior year.
- Net Cash Flow improved to $3.5 million in Q1 2026 per OABI's latest filing, from -$3.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $33.8 million in Q4 2022 and bottomed at -$16.7 million in Q1 2025.
- Historically, Net Cash Flow has averaged $2.1 million across 5 years, with a median of $1.0 million in 2024.
- Annual changes were most pronounced in 2022 — Net Cash Flow soared 9442.55% — and 2025, when it plunged 932.32%.
- OmniAb's Net Cash Flow stood at $33.8 million in 2022, then tumbled by 114.44% to -$4.9 million in 2023, then surged by 107.41% to $362000.0 in 2024, then slumped by 932.32% to -$3.0 million in 2025, then soared by 216.89% to $3.5 million in 2026.
- Business Quant data shows OABI's Net Cash Flow at $3.5 million in Q1 2026, -$3.0 million in Q4 2025, and $10.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | -4.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.71 Mn |
| Jun 30, 2026 | -4.71 Mn |
| Mar 31, 2026 | 3.52 Mn |
| Mar 31, 2026 | 3.52 Mn |
| Dec 31, 2025 | -3.01 Mn |
| Dec 31, 2025 | -3.01 Mn |
| Sep 30, 2025 | 10.26 Mn |
| Sep 30, 2025 | 10.26 Mn |
| Jun 30, 2025 | 7.39 Mn |
| Jun 30, 2025 | 7.39 Mn |
| Mar 31, 2025 | -16.71 Mn |
| Mar 31, 2025 | -16.71 Mn |
| Dec 31, 2024 | 362,000.00 |
| Dec 31, 2024 | 362,000.00 |
| Sep 30, 2024 | 6.44 Mn |
| Sep 30, 2024 | 6.44 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 2.70 Mn |
| Mar 31, 2024 | 2.70 Mn |